Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer
Studies Shed Light On Racial Disparities Between Blacks, Whites With Breast Cancer
Shorter, Simpler Consent Form Proposed For Phase I Trials
How Much Is Life Worth? The $440 Billion Question
Sunitinib Prolongs Survival In Poor Prognosis, Study Finds
Breast MRI Recipients More Likely To Choose Mastectomy
Opioid Pain Reliever Approved With Risk Reduction Plan
NCI Cooperative Group Clinical Trials Approved
Trending Stories
- Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutions
The move could gut academic cancer research - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - “Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions” - 20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
- Preparing to take care of each other in ways we never imagined